SoftOx Solutions AS: Clarification on Placement Commission

Reference is made to the stock exchange announcement on 25 September 2025 regarding the private placement under the financing facility with Long State Investments Limited.

For clarity, the reference to a “placement commission on market terms” relates to the standard transaction cost that applies when raising capital through such facilities/underwriters. This type of commission is customary in the capital markets and comparable to underwriting fees in larger placements. It does not represent a special benefit to Long State but reflects the normal compensation all underwriters receive when facilitating capital raises.

For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com

About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.